Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Operating Margin (2018 - 2025)

Autolus Therapeutics' Operating Margin history spans 5 years, with the latest figure at 298.35% for Q4 2025.

  • For Q4 2025, Operating Margin rose 26130165.0% year-over-year to 298.35%; the TTM value through Dec 2025 reached 358.87%, up 202464.0%, while the annual FY2025 figure was 358.87%, 202676.0% up from the prior year.
  • Operating Margin reached 298.35% in Q4 2025 per AUTL's latest filing, up from 337.93% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 292.58% in Q2 2025 to a low of 261600.0% in Q4 2024.
  • Average Operating Margin over 4 years is 33226.17%, with a median of 726.34% recorded in 2025.
  • The largest YoY upside for Operating Margin was 26130165bps in 2025 against a maximum downside of -34261bps in 2025.
  • A 4-year view of Operating Margin shows it stood at 21798.8% in 2022, then surged by 52bps to 10567.73% in 2023, then plummeted by -2375bps to 261600.0% in 2024, then soared by 100bps to 298.35% in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Operating Margin are 298.35% (Q4 2025), 337.93% (Q3 2025), and 292.58% (Q2 2025).